Syngene International reported a 20% decline in profit after tax for fiscal year 2026, dropping to ₹379.9 crore, despite a 3% rise in revenue to ₹3,738.7 crore.
The divergence between top-line growth and bottom-line contraction underscores the persistent margin pressure facing contract research organizations as clients continue to normalize inventory levels.
This result aligns with broader concerns in the Indian pharmaceutical services sector, where several peers have reported similar margin compression.
The company attributed the profit slump to destocking activities among its key clients, a trend that has dampened pricing power and utilization rates across the sector.
While revenue growth indicates underlying demand remains intact, the inability to translate that volume into proportional earnings suggests that the industry is still navigating a post-pandemic correction phase.
This result aligns with broader concerns in the Indian pharmaceutical services sector, where several peers have reported similar margin compression.
Investors are increasingly scrutinizing the sustainability of growth rates when cost structures and client spending habits remain volatile.